Overview

Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease

Status:
Terminated
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
This study is designed to explore mechanism of action of mongersen (GED-0301) 160 mg once daily in patients with active Crohn's Disease
Phase:
Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation